TW201410676A - 芳基內醯胺激酶抑制劑 - Google Patents

芳基內醯胺激酶抑制劑 Download PDF

Info

Publication number
TW201410676A
TW201410676A TW102127296A TW102127296A TW201410676A TW 201410676 A TW201410676 A TW 201410676A TW 102127296 A TW102127296 A TW 102127296A TW 102127296 A TW102127296 A TW 102127296A TW 201410676 A TW201410676 A TW 201410676A
Authority
TW
Taiwan
Prior art keywords
amino
naphthyridin
group
oxy
alkyl
Prior art date
Application number
TW102127296A
Other languages
English (en)
Chinese (zh)
Inventor
菲佛卡南達M 福魯赫拉
潘森梁
羅庫瑪 雷賈曼恩
瑟斯希爾 傑森安德 那拉
瑪希斯瓦倫 希法沙賓 卡拉索魯胡
塔朗 庫瑪 梅修
強納森L 迪塔
卡洛琳 戴安 德茲爾巴
瓊安J 布朗森
約翰E 馬可
Original Assignee
必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 必治妥美雅史谷比公司 filed Critical 必治妥美雅史谷比公司
Publication of TW201410676A publication Critical patent/TW201410676A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW102127296A 2012-07-31 2013-07-30 芳基內醯胺激酶抑制劑 TW201410676A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261677856P 2012-07-31 2012-07-31
US13/946,344 US8901305B2 (en) 2012-07-31 2013-07-19 Aryl lactam kinase inhibitors

Publications (1)

Publication Number Publication Date
TW201410676A true TW201410676A (zh) 2014-03-16

Family

ID=50026068

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102127296A TW201410676A (zh) 2012-07-31 2013-07-30 芳基內醯胺激酶抑制劑

Country Status (12)

Country Link
US (1) US8901305B2 (enExample)
EP (1) EP2880032B1 (enExample)
JP (1) JP2015528018A (enExample)
CN (1) CN104507941A (enExample)
AR (1) AR093758A1 (enExample)
BR (1) BR112015001890A2 (enExample)
CA (1) CA2880523A1 (enExample)
EA (1) EA201590268A1 (enExample)
ES (1) ES2602965T3 (enExample)
MX (1) MX2015000980A (enExample)
TW (1) TW201410676A (enExample)
WO (1) WO2014022167A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708337B2 (en) 2013-02-22 2017-07-18 Bristol-Myers Squibb Company Aryl amide-based kinase inhibitors
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN106132414A (zh) * 2014-01-29 2016-11-16 百时美施贵宝公司 芳基内酰胺激酶抑制剂
CA2944466C (en) 2014-04-02 2020-06-09 Bristol-Myers Squibb Company Biaryl kinase inhibitors
EP3292124B1 (en) * 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
EP3356330B1 (en) * 2015-10-01 2019-11-20 Bristol-Myers Squibb Company Biaryl kinase inhibitors
CN108368084B (zh) * 2015-10-01 2020-10-16 百时美施贵宝公司 联芳基激酶抑制剂
WO2021026349A1 (en) * 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
CN114853664B (zh) * 2022-06-02 2023-09-29 河南大学 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法
CN116102542A (zh) * 2023-02-15 2023-05-12 如东众意化工有限公司 环丙唑醇精制母液中环丙唑醇的回收方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
BR9307570A (pt) 1992-12-02 1999-05-25 Pfizer Diéteres de catecol como inibidores seletivos de pdeiv
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
CA2477692A1 (en) 2002-04-05 2003-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
CA2555287A1 (en) * 2004-02-18 2005-08-25 David Garrett Loughhead Heterocyclic gaba-a subtype selective receptor modulators
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
KR20080063833A (ko) * 2005-12-15 2008-07-07 에프. 호프만-라 로슈 아게 트리시클릭 락탐 유도체, 이의 제조 및 약학적 제제로서의용도
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
CA2645031A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
US7776905B2 (en) 2006-04-07 2010-08-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2008022155A2 (en) 2006-08-14 2008-02-21 Wyeth Methods of identifying agents for treating neurological disorders
WO2008079933A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
CA2761298A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
JP5752232B2 (ja) * 2010-03-31 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
DK2822555T3 (en) 2012-03-09 2018-02-05 Lexicon Pharmaceuticals Inc Inhibition of adapter-associated kinase 1 for the treatment of pain
NZ630719A (en) 2012-03-09 2017-01-27 Lexicon Pharmaceuticals Inc Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
IN2014DN07384A (enExample) 2012-03-09 2015-04-24 Lexicon Pharmaceuticals Inc

Also Published As

Publication number Publication date
ES2602965T3 (es) 2017-02-23
JP2015528018A (ja) 2015-09-24
EP2880032B1 (en) 2016-10-05
US20140038999A1 (en) 2014-02-06
CA2880523A1 (en) 2014-02-06
EP2880032A1 (en) 2015-06-10
WO2014022167A1 (en) 2014-02-06
CN104507941A (zh) 2015-04-08
EA201590268A1 (ru) 2015-05-29
BR112015001890A2 (pt) 2017-07-04
AR093758A1 (es) 2015-06-24
MX2015000980A (es) 2015-04-10
US8901305B2 (en) 2014-12-02

Similar Documents

Publication Publication Date Title
CN106458994B (zh) 联芳激酶抑制剂
CN108290843B (zh) 联芳基激酶抑制剂
TWI702218B (zh) 選擇性經取代之喹啉化合物
CN108368084B (zh) 联芳基激酶抑制剂
CN102548557B (zh) 用于降低β-淀粉状蛋白生成的化合物
CN110156772B (zh) 一种杂环化合物、其应用及含其的药物组合物
WO2024083258A1 (zh) Kras g12d降解剂及其制备方法和应用
TWI639602B (zh) 三環旋轉酶抑制劑
CN105939997B (zh) 作为dlk抑制剂的吡唑衍生物及其用途
TWI480282B (zh) 稠合雜環衍生物及其用途
CN113227068A (zh) Glp-1r激动剂及其用途
CN104507941A (zh) 芳基内酰胺激酶抑制剂
CN105517993B (zh) 芳基酰胺激酶抑制剂
CN106132414A (zh) 芳基内酰胺激酶抑制剂
TW201414737A (zh) 作爲激酶抑制劑之咪唑并三□甲腈
TW201434825A (zh) 3-取代吡唑及其用途
TW201341385A (zh) 咪唑[1,2-b]噠嗪基化合物、包含其之組成物及其使用方法
JP2023501399A (ja) ヘテロ環式rip1阻害化合物
CN110461842A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
CN111032641A (zh) 经取代的5-氰基吲哚化合物及其用途
CN107108552A (zh) 杂环激酶抑制剂
CN117881683A (zh) PI3Kα抑制剂及其使用方法
CN103896946A (zh) 用于预防及治疗多种自身免疫疾病的新化合物
TW201609698A (zh) 三環磺醯胺衍生物
RS62533B1 (sr) Farmakološki aktivni aliciklično-supstituisani derivati pirazolo[1,5-a]pirimidina